Advertisement

Hereditary Cancers in Gynecology

What Physicians Should Know About Genetic Testing, Screening, and Risk Reduction

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Walsh T.
        • Casadei S.
        • Lee M.K.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc Natl Acad Sci U S A. 2011; 108: 18032-18037
        • King M.C.
        • Marks J.H.
        • Mandell J.B.
        Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
        Science. 2003; 302: 643-646
        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Ford D.
        • Easton D.F.
        • Stratton M.
        • et al.
        Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.
        Am J Hum Genet. 1998; 62: 676-689
      1. SGO Clinical Practice Statement: Genetic testing for ovarian cancer. Available at: https://www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/. Accessed October 24, 2016.

      2. NCCN Guidelines Genetic/Familial High-Risk Assessment: breast and ovarian version 1.2017 2016; Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed September 1, 2017.

        • Stadler Z.K.
        • Salo-Mullen E.
        • Patil S.M.
        • et al.
        Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
        Cancer. 2012; 118: 493-499
        • Mersch J.
        • Jackson M.A.
        • Park M.
        • et al.
        Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
        Cancer. 2015; 121: 269-275
        • Shu C.A.
        • Pike M.C.
        • Jotwani A.R.
        • et al.
        Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations.
        JAMA Oncol. 2016; 2: 1434-1440
        • Loveday C.
        • Turnbull C.
        • Ramsay E.
        • et al.
        Germline mutations in RAD51D confer susceptibility to ovarian cancer.
        Nat Genet. 2011; 43: 879-882
        • Loveday C.
        • Turnbull C.
        • Ruark E.
        • et al.
        Germline RAD51C mutations confer susceptibility to ovarian cancer.
        Nat Genet. 2012; 44: 475-476
        • Ramus S.J.
        • Song H.
        • Dicks E.
        • et al.
        Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer.
        J Natl Cancer Inst. 2015; 107: djv214
        • Tiwari A.K.
        • Roy H.K.
        • Lynch H.T.
        Lynch syndrome in the 21st century: clinical perspectives.
        QJM. 2016; 109: 151-158
      3. NCCN Clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal. 2016; Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed October 11, 2016.

        • Barrow E.
        • Hill J.
        • Evans D.G.
        Cancer risk in Lynch syndrome.
        Fam Cancer. 2013; 12: 229-240
        • Lu K.H.
        • Dinh M.
        • Kohlmann W.
        • et al.
        Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome.
        Obstetrics Gynecol. 2005; 105: 569-574
        • Chui M.H.
        • Gilks C.B.
        • Cooper K.
        • et al.
        Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype.
        Adv Anat Pathol. 2013; 20: 378-386
        • Chui M.H.
        • Ryan P.
        • Radigan J.
        • et al.
        The histomorphology of Lynch syndrome–associated ovarian carcinomas: toward a subtype-specific screening strategy.
        Am J Surg Pathol. 2014; 38: 1173-1181
      4. SGO Clinical Practice Statement: screening for Lynch syndrome in endometrial cancer. Available at: https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer/. Accessed October 24, 2016.

        • Palles C.
        • Cazier J.B.
        • Howarth K.M.
        • et al.
        Germline mutations affecting the proofreading domains of pole and pold1 predispose to colorectal adenomas and carcinomas.
        Nat Genet. 2013; 45: 136-144
        • Briggs S.
        • Tomlinson I.
        Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers.
        J Pathol. 2013; 230: 148-153
        • Bellido F.
        • Pineda M.
        • Aiza G.
        • et al.
        POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
        Genet Med. 2016; 18: 325-332
        • Tan M.H.
        • Mester J.L.
        • Ngeow J.
        • et al.
        Lifetime cancer risks in individuals with germline PTEN mutations.
        Clin Cancer Res. 2012; 18: 400-407
        • van Lier M.G.
        • Wagner A.
        • Mathus-Vliegen E.M.
        • et al.
        High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.
        Am J Gastroenterol. 2010; 105: 1258-1264
        • Resta N.
        • Pierannunzio D.
        • Lenato G.M.
        • et al.
        Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.
        Dig Liver Dis. 2013; 45: 606-611
        • McGarrity T.J.
        • Kulin H.E.
        • Zaino R.J.
        Peutz-Jeghers syndrome.
        Am J Gastroenterol. 2000; 95: 596-604
        • Laptenko O.
        • Prives C.
        p53: master of life, death, and the epigenome.
        Genes Development. 2017; 31: 955-956
        • Villani A.
        • Tabori U.
        • Schiffman J.
        • et al.
        Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
        Lancet Oncol. 2011; 12: 559-567
        • Kratz C.P.
        • Achatz M.I.
        • Brugières L.
        • et al.
        Cancer screening recommendations for individuals with Li-Fraumeni syndrome.
        Clin Cancer Res. 2017; 23: e38-e45
        • Villani A.
        • Shore A.
        • Wasserman J.D.
        • et al.
        Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
        Lancet Oncol. 2016; 17: 1295-1305
        • Olivier M.
        • Goldgar D.E.
        • Sodha N.
        • et al.
        Li-Fraumeni and related syndromes. Correlation between tumor type, family structure, and TP53 genotype.
        Cancer Res. 2003; 63: 6643-6650
      5. ACOG Practice Bulletin No 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2017;130(3);e110–26.

        • Norquist B.M.
        • Harrell M.I.
        • Brady M.F.
        • et al.
        Inherited mutations in women with ovarian carcinoma.
        JAMA Oncol. 2016; 2: 482-490
        • Leenen C.H.
        • van Lier M.G.
        • van Doorn H.C.
        • et al.
        Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
        Gynecol Oncol. 2012; 125: 414-420
        • Saslow D.
        • Boetes C.
        • Burke W.
        • et al.
        American cancer society guidelines for breast screening with MRI as an adjunct to mammography.
        CA Cancer J Clinicians. 2007; 57: 75-89
        • Buys S.S.
        • Partridge E.
        • Black A.
        • et al.
        Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial.
        JAMA. 2011; 305: 2295-2303
        • Partridge E.
        • Kreimer A.R.
        • Greenlee R.T.
        • et al.
        Results from four rounds of ovarian cancer screening in a randomized trial.
        Obstetrics Gynecol. 2009; 113: 775-782
        • Fishman D.A.
        • Cohen L.
        • Blank S.V.
        • et al.
        The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
        Am J Obstetrics Gynecol. 2005; 192: 1214-1221
        • Johnson C.C.
        • Kessel B.
        • Riley T.L.
        • et al.
        The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
        Gynecol Oncol. 2008; 110: 383-389
        • Skates S.J.
        • Greene M.H.
        • Buys S.S.
        • et al.
        Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk: combined results from two screening trials.
        Clin Cancer Res. 2017; 23: 3628-3637
        • Rosenthal A.N.
        • Fraser L.S.M.
        • Philpott S.
        • et al.
        Evidence of stage shift in women diagnosed with ovarian cancer during phase ii of the United Kingdom familial ovarian cancer screening study.
        J Clin Oncol. 2017; 35: 1411-1420
        • Renkonen-Sinisalo L.
        • Bützow R.
        • Leminen A.
        • et al.
        Surveillance for endometrial cancer in the hereditary nonpolyposis colorectal cancer syndrome.
        Int J Cancer. 2007; 120: 821-824
        • Gerritzen L.H.
        • Hoogerbrugge N.
        • Oei A.L.
        • et al.
        Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.
        Fam Cancer. 2009; 8: 391
        • Dove-Edwin I.
        • Boks D.
        • Goff S.
        • et al.
        The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.
        Cancer. 2002; 94: 1708-1712
        • Kauff N.D.
        • Satagopan J.M.
        • Robson M.E.
        • et al.
        Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
        New Engl J Med. 2002; 346: 1609-1615
        • Kauff N.D.
        • Domchek S.M.
        • Friebel T.M.
        • et al.
        Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
        J Clin Oncol. 2008; 26: 1331-1337
        • Domchek S.M.
        • Friebel T.M.
        • Neuhausen S.L.
        • et al.
        Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
        Lancet Oncol. 2006; 7: 223-229
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA. 2010; 304: 967-975
        • Finch A.P.
        • Lubinski J.
        • Møller P.
        • et al.
        Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
        J Clin Oncol. 2014; 32: 1547-1553
        • Kwon J.S.
        • Tinker A.
        • Pansegrau G.
        • et al.
        Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
        Obstetrics Gynecol. 2013; 121: 14-24
        • Holman L.L.
        • Friedman S.
        • Daniels M.S.
        • et al.
        Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.
        Gynecol Oncol. 2014; 133: 283-286
        • Hartmann L.C.
        • Lindor N.M.
        The role of risk-reducing surgery in hereditary breast and ovarian cancer.
        New Engl J Med. 2016; 374: 454-468
        • Iodice S.
        • Barile M.
        • Rotmensz N.
        • et al.
        Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
        Eur J Cancer. 2010; 46: 2275-2284
        • Friebel T.M.
        • Domchek S.M.
        • Rebbeck T.R.
        Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: a systematic review and meta-analysis.
        J Natl Cancer Inst. 2014; 106: dju091
        • King M.
        • Wieand S.
        • Hale K.
        • et al.
        Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial.
        JAMA. 2001; 286: 2251-2256
        • Fisher B.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • Nelson H.D.
        • Smith M.
        • Griffin J.C.
        • et al.
        Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. preventive services task force.
        Ann Intern Med. 2013; 158: 604-614
        • Vogel V.G.
        • Costantino J.P.
        • Wickerham D.
        • et al.
        Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) p-2 trial.
        JAMA. 2006; 295: 2727-2741
        • Vogel V.G.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer.
        Cancer Prev Res (Phila). 2010; 3: 696-706
        • Freedman A.N.
        • Yu B.
        • Gail M.H.
        • et al.
        Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
        J Clin Oncol. 2011; 29: 2327-2333
        • Cuzick J.
        • Sestak I.
        • Forbes J.F.
        • et al.
        Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
        Lancet. 2014; 383: 1041-1048
        • Goss P.E.
        • Ingle J.N.
        • Alés-Martínez J.E.
        • et al.
        Exemestane for breast-cancer prevention in postmenopausal women.
        New Engl J Med. 2011; 364: 2381-2391
        • Schmeler K.M.
        • Lynch H.T.
        • Chen L.M.
        • et al.
        Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
        New Engl J Med. 2006; 354: 261-269
        • Chen L.M.
        • Yang K.Y.
        • Little S.E.
        • et al.
        Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families.
        Obstet Gynecol. 2007; 110: 18-25
        • Committee on Practice Bulletins-Gynecology
        • Society of Gynecologic Oncology
        ACOG Practice bulletin no. 147: Lynch syndrome.
        Obstetrics Gynecol. 2014; 124: 1042-1054
        • Havrilesky L.J.
        • Gierisch J.M.
        • Moorman P.G.
        • et al.
        Oral contraceptive use for the primary prevention of ovarian cancer.
        Evid Rep Tevhnol Assess (Full Rep). 2013; 212: 1-514
        • Collaborative Group on Epidemiological Studies on Endometrial Cancer
        Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.
        Lancet Oncol. 2015; 16: 1061-1070